FREE PSA AND CLINICALLY SIGNIFICANT ANDFATAL PROSTATE CANCER IN THE PLCO SCREENING TRIAL

被引：0
|
作者：
Yim, Kendrick
Ma, Chaoran
Carlsson, Sigrid
Lilja, Hans
D'Andrea, Vincent
Mucci, Lorelei
Penney, Kathryn
Preston, Mark
机构：
来源：
JOURNAL OF UROLOGY | 2023年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD38-09
引用
收藏
页码：E996 / E997
页数：2
相关论文
共 50 条
  • [21] Seminal citrate is superior to PSA for detecting clinically significant prostate cancer
    Gregorio, Emerson Pereira
    Alexandrino, Antonio Paulo
    Albrecht Schuquel, Ivania Terezinha
    da Costa, Willian Ferreira
    de Freitas Rodrigues, Marco Aurelio
    INTERNATIONAL BRAZ J UROL, 2019, 45 (06): : 1113 - 1121
  • [22] Serum metabolomic profiling of prostate cancer risk in the PLCO Cancer Screening Trial
    Mondul, Alison M.
    Koutros, Stella
    Weinstein, Stephanie J.
    Berndt, Sonja I.
    Albanes, Demetrius
    CANCER RESEARCH, 2016, 76
  • [23] PSA testing interval, reduction in screening intervals: Data from the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.
    Crawford, D
    Chia, D
    Andriole, GL
    Reding, D
    Gelmann, EP
    Gohagan, JK
    Pinsky, P
    Hayes, RB
    Levin, DL
    Fagerstrom, RM
    Kramer, B
    JOURNAL OF UROLOGY, 2002, 167 (04): : 99 - 100
  • [24] Prostate cancer risk and initial treatment decisions in the PLCO cancer screening trial
    Grubb, Robert L.
    Miller, David C.
    Church, Timothy R.
    Hickey, Thomas
    Greenlee, Robert T.
    Lzmirlian, Grant
    Mabie, Jerome
    Riley, Thomas L.
    Ragard, Lawrence
    Prorok, Philip C.
    Berg, Christine D.
    Crawford, E. David
    Andriole, Gerald L.
    JOURNAL OF UROLOGY, 2008, 179 (04): : 153 - 153
  • [25] The prostate, lung, colorectal and ovarian (PLCO) cancer screening trial - Preface
    Gohagan, JK
    CONTROLLED CLINICAL TRIALS, 2000, 21 (06): : 249S - 250S
  • [26] Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mL
    Sii, Samuel
    Papa, Nathan
    Yiu, Ting Wai
    Tempo, Jake
    Qu, Liang
    Perera, Marlon
    Thompson, Ian
    Ischia, Joseph
    Fleshner, Neil
    Smith, Elliot
    Ranasinghe, Weranja
    Bolton, Damien
    Woon, Dixon T. S.
    BJU INTERNATIONAL, 2025, 135 (04) : 550 - 556
  • [27] Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
    Prorok, PC
    Andriole, GL
    Bresalier, RS
    Buys, SS
    Chia, D
    Crawford, ED
    Fogel, R
    Gelmann, EP
    Gilbert, F
    Hasson, MA
    Hayes, RB
    Johnson, CC
    Mandel, JS
    Oberman, A
    O'Brien, B
    Oken, MM
    Rafla, S
    Reding, D
    Rutt, W
    Weissfeld, JL
    Yokochi, L
    Gohagan, JK
    CONTROLLED CLINICAL TRIALS, 2000, 21 (06): : 273S - 309S
  • [28] Lung Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
    Hocking, William G.
    Hu, Ping
    Oken, Martin M.
    Winslow, Stephen D.
    Kvale, Paul A.
    Prorok, Philip C.
    Ragard, Lawrence R.
    Commins, John
    Lynch, David A.
    Andriole, Gerald L.
    Buys, Saundra S.
    Fouad, Mona N.
    Fuhrman, Carl R.
    Isaacs, Claudine
    Yokochi, Lance A.
    Riley, Thomas L.
    Pinsky, Paul F.
    Gohagan, John K.
    Berg, Christine D.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (10): : 722 - 731
  • [29] Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
    Pinsky, Paul F.
    Black, Amanda
    Parnes, Howard L.
    Grubb, Robert
    Crawford, E. David
    Miller, Anthony
    Reding, Douglas
    Andriole, Gerald
    CANCER EPIDEMIOLOGY, 2012, 36 (06) : E401 - E406
  • [30] Predictors of Clinically Significant Prostate Cancer: A Comparative Study of PSA, PSA Density, and MRI Parameters
    Coskun, Mehmet
    Donmez, Emine Merve Horoz
    Akin, Yigit
    Ocal, Irfan
    Gumus, Cesur
    Uluc, Muhsin Engin
    ISTANBUL MEDICAL JOURNAL, 2021, 22 (01): : 31 - 37
12345